Recombinant Vibrio cholerae strains with impaired GlcNAc utilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines and control methods for Vibrio cholerae are inadequate in providing effective immunity and prevention against cholera, as they do not effectively inhibit the pathogen's ability to colonize and persist in the host.
Innovation Solution
Development of recombinant strains of Vibrio cholerae with mutations in genes involved in N-acetylglucosamine (GlcNAc) catabolism, such as nagA1, nagA2, nagB, nagE, and nagC, which impair the bacteria's ability to utilize GlcNAc, thereby reducing its colonization capacity and virulence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant strains of Vibrio cholerae with mutations in GlcNAc catabolism genes are developed, then the bacteria's colonization capacity and virulence are reduced, but the vaccine effectiveness is improved
Solution Approach 1:
The patent extracts and removes the functional capability of GlcNAc catabolism from the Vibrio cholerae strain by introducing mutations in key genes (nagA1, nagA2, nagB, nagE, nagC). This extraction of metabolic function directly reduces the bacteria's ability to utilize GlcNAc, thereby diminishing its colonization capacity while preserving it as a vaccine candidate.
Solution Approach 2:
The patent changes the metabolic parameters of Vibrio cholerae by altering the enzymatic activities in the GlcNAc catabolic pathway through gene mutations. These parameter changes (loss of enzymatic function) fundamentally modify the bacteria's nutritional metabolism, reducing its fitness and colonization ability in the host intestine.
2Adaptability or versatility
If mutations are introduced in GlcNAc catabolism genes (nagA1, nagA2, nagB, nagE, nagC), then the ability to utilize GlcNAc is impaired, but the bacteria remains viable for vaccine use
Solution Approach 1:
The patent segments the GlcNAc catabolic pathway into multiple functional components (transporters nagE, deacetylases nagA1/nagA2, deaminases nagB, and regulators nagC). By introducing mutations in individual segments rather than the entire pathway, the bacteria retains partial metabolic flexibility while losing the specific GlcNAc utilization capability needed for colonization.
3Object-generated harmful factors
If recombinant strains with impaired GlcNAc utilization are created, then colonization is reduced, but virulence gene expression is maintained
Solution Approach 1:
The patent extracts the metabolic function of GlcNAc catabolism from the Vibrio cholerae strain through gene mutations, while deliberately preserving the virulence gene expression machinery. This selective extraction removes only the nutritional metabolism component responsible for colonization, leaving the virulence factors intact and expressible.
Solution Approach 2:
The patent applies local quality changes by targeting specific metabolic genes (nagA1, nagA2, nagB, nagE, nagC) for mutation while leaving other genomic regions, particularly those encoding virulence factors, unchanged. This localized genetic modification ensures that colonization ability is reduced without compromising virulence gene expression.
Data Source
AI summary
The present invention relates to recombinant strains of Vibrio spp, which are unable to utilize the amino sugar N-acetylglucosamine (GlcNAc) as a sole carbon source. This inability to utilize GlcNAc severely impairs the colonization property of the recombinants. The present invention also provides compositions comprising these recombinant strains for use in pharmaceuticals and in providing immunity.